These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16099272)

  • 1. Valproic acid: a potential role in treating latent HIV infection.
    Routy JP
    Lancet; 2005 Aug 13-19; 366(9485):523-4. PubMed ID: 16099272
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
    Cohen J
    Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
    Sagot-Lerolle N; Lamine A; Chaix ML; Boufassa F; Aboulker JP; Costagliola D; Goujard C; Pallier C; Delfraissy JF; Lambotte O;
    AIDS; 2008 Jun; 22(10):1125-9. PubMed ID: 18525257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 5. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    Archin NM; Eron JJ; Palmer S; Hartmann-Duff A; Martinson JA; Wiegand A; Bandarenko N; Schmitz JL; Bosch RJ; Landay AL; Coffin JM; Margolis DM
    AIDS; 2008 Jun; 22(10):1131-5. PubMed ID: 18525258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New research finds possible treatment for latent HIV. Valproic acid used to deplete HIV.
    AIDS Alert; 2005 Dec; 20(12):136-8. PubMed ID: 16397938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
    Lehrman G; Hogue IB; Palmer S; Jennings C; Spina CA; Wiegand A; Landay AL; Coombs RW; Richman DD; Mellors JW; Coffin JM; Bosch RJ; Margolis DM
    Lancet; 2005 Aug 13-19; 366(9485):549-55. PubMed ID: 16099290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
    Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
    J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
    Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
    HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Valproic acid and HIV eradication--many questions remain.
    TreatmentUpdate; 2005; 17(6):5-7. PubMed ID: 17228476
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    Archin NM; Cheema M; Parker D; Wiegand A; Bosch RJ; Coffin JM; Eron J; Cohen M; Margolis DM
    PLoS One; 2010 Feb; 5(2):e9390. PubMed ID: 20186346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing medications for use in treating HIV infection: A focus on valproic acid as a latency-reversing agent.
    Crosby B; Deas CM
    J Clin Pharm Ther; 2018 Oct; 43(5):740-745. PubMed ID: 29959785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of HIV despite the discontinuation of antiretroviral therapy.
    Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
    N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
    [No Abstract]   [Full Text] [Related]  

  • 14. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
    Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
    Siliciano JD; Lai J; Callender M; Pitt E; Zhang H; Margolick JB; Gallant JE; Cofrancesco J; Moore RD; Gange SJ; Siliciano RF
    J Infect Dis; 2007 Mar; 195(6):833-6. PubMed ID: 17299713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliminating HIV-1 reservoirs.
    Pomerantz RJ
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1133-7. PubMed ID: 12211403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.